Vaxart
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
310 Utah Ave Ste 150, South San Francisc...Phone Number
(650) 550-3500Website
www.vaxart.comRevenue
$237.3 MillionStock Symbol
VXRTIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Vaxart
Vaxart is a biotechnology company focused on developing oral vaccines delivered in pill form to help prevent infectious diseases and improve vaccine accessibility. Using its proprietary delivery platform, the company develops vaccines for conditions such as coronavirus, norovirus, influenza, and human papillomavirus, aiming to provide convenient, needle-free immunization solutions.Explore more
Vaxart Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vaxart your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Vaxart recently announced quarterly report
Product Launch: Get notified when Vaxart launches new products
Vaxart, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Vaxart
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Vaxart had a recent Job posting/layoffs
Check if Vaxart has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Vaxart has new funding data
Check out if Vaxart is spiking on competitors!
Recommended Actions
Find VP level buyers at Vaxart
Find more new buyers
Compare Similar Companies to Vaxart
Compare insights from companies similar to Vaxart, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vaxart is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Vaxart is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Vaxart.
Vaxart financials insights
Gather financial insights about Vaxart, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Series A
$3.3M
2012
Series B
$16.9M
2014
Stock Offering
$26.9M
2019
Multiple Rounds
$21.3M
2020
Stock Offering
$10M
Debt
$90M
Vaxart Tech Stack
A closer look at the technologies used by Vaxart
Most Recent Scoops
Person-Based
Events
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Financial Planning, Financial Reporting, Business Finance, Finance
Person-Based
Executive Moves, Earnings, Finance
Vaxart News & Media
Vaxart to Participate in BTIG Biotechnology Conference 2026
SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in the BTIG Virtual Biotechnology Conference taking place virtually July 28, 2026.Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now
Vaxart (OTCMKTS:VXRT) held its 2026 Annual Meeting of Stockholders, where investors re-elected the company’s full slate of directors, ratified its auditor and rejected the company’s non-binding advisory proposal on executive compensation. Mark Watson, Vaxart’s lead independent director and chair ofVaxart Announces Results of Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vaxart
Sign Up For FreeTo access detailed company insights
Vaxart is a biotechnology company focused on developing oral vaccines delivered in pill form to help prevent infectious diseases and improve vaccine accessibility. Using its proprietary delivery platform, the company develops vaccines for conditions such as coronavirus, norovirus, influenza, and human papillomavirus, aiming to provide convenient, n... Read More
